Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31204632 | 1.00 | CHRNA7 (0.66) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL7563225 | 0.95 | CHRNA7 (0.65) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL7526106 | 0.95 | CHRNA7 (0.65) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL7832435 | 0.95 | CHRNA7 (0.65) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL7560367 | 0.95 | CHRNA7 (0.65) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL31011774 | 0.95 | CHRNA7 (0.64) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL31011771 | 0.95 | CHRNA7 (0.64) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| Oxalic Acid SCHEMBL7650708 | 0.92 | CHRNA7 (0.60) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| Oxalic Acid SCHEMBL7650711 | 0.92 | CHRNA7 (0.60) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL1307195 | 0.90 | TAAR1 (0.69) | CHRNA7TAAR1OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20210323913-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-21 | — | — | US | disclosed |
| EP-3886845-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020112581-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020112581-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-5780470-A | TREATING SLEEP DISORDERS AND DEPRESSION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0745597-A2 | Novel melatonergic indanyl piperazines or homopiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0649419-A1 | N-CYCLOALKYLPIPERAZINE DERIVATIVES, METHODS OF OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES MERAM (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994002473-A1 | N-CYCLOALKYLPIPERAZINE DERIVATIVES, METHODS OF OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES MERAM (FR) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | CHRNA7 20/4885TAAR1 94/4885OPRM1 14/4885 |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | CHRNA7 82/4885TAAR1 31/4885OPRM1 32/4885 |
| US-20210323913-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | CHRNA7 36/4885TAAR1 10/4885OPRM1 4/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | CHRNA7 48/4885TAAR1 144/4885OPRM1 15/4885 |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | CHRNA7 2506/4885TAAR1 1199/4885OPRM1 2756/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | CHRNA7 2716/4885TAAR1 1503/4885OPRM1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.